Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments

Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has announced the selection of a Contract Research Organization (CRO) to conduct in vitro studies on the effectiveness of its DuraCAR cells. The experiments will focus on the immunosuppressive and tumor-killing capabilities of the cells, aiming to determine their potential in cancer treatment. Dr. David Koos, Chairman and CEO, expressed confidence in the chosen CRO and expects the results to provide valuable insights for the program's advancement.

SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells.

The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments.  The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing.  In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells.

"We have designed a set of sophisticated experiments that test two hypotheses" says Dr. David Koos, Chairman and CEO of the company. "We have selected a CRO with excellent credentials and we expect the results to lay a clear path forward for this program."

About Regen BioPharma Inc.: 

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION:

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or david.koos@regenbiopharma.com
Twitter (now X): https://twitter.com/TheRegenBio

View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-selects-contract-research-organization-to-assist-in-duracar-experiments-301989889.html

SOURCE Regen BioPharma Inc.

FAQ

What experiments is Regen BioPharma, Inc. conducting on its DuraCAR cells?

The company is preparing in vitro studies to test the immunosuppressive and tumor-killing effects of its DuraCAR cells.

Who is leading the program at Regen BioPharma, Inc.?

Dr. David Koos, the Chairman and CEO, is overseeing the program.

What are the expectations from the selected CRO?

The company anticipates that the results from the CRO's experiments will provide a clear path forward for the DuraCAR cells program.